The effect of coagulation protection with combination of epsilon aminocaproic acid and plasma saver in open-heart surgery. 1998

Y C Liu, and T P Tsai
Department of Anesthesiology, China Medical College Hospital, Taichung, Taiwan, R.O.C.

BACKGROUND Bleeding remains a major complication and a major determinant in the prognosis of open-heart surgery. Coagulopathy related to cardiopulmonary bypass (CPB) seems to be the culprit. Since homologous blood transfusion in many occasions is not only responsible for mobidity and mortality but also increases medical costs. Therefore, the application of autologous blood transfusion including components such as PRBC, FFP and platelets concentrate is inevitable and comes in its stead. To reduce the use of homologous plasma and platelets transfusion in open-heart surgery, we designed a study to utilize the combination of autologous platelet rich plasma (PRP) and epsilon aminocaproic acid (EACA) to evaluate its effects on blood loss and blood component transfusion in open-heart patients. METHODS Sixty patients who received elective cardiac surgery were randomly divided into 3 groups: 1. Control group; 2. EACA group (150 mg/kg, i.v. before CPB); 3. PRP-EACA group (PRP 10 ml/kg harvested with a plasma saver followed by i.v. EACA 150 mg/kg). Anesthesia was uniform in all patients. Coagulation profile was evaluated by thromboelastography (TEG) during the operation. Blood loss during operation and the amount of drainage from the chest tubes in the postoperative period were recorded and compared between groups. RESULTS Patients who were given EACA injection before CPB saw less blood loss perioperatively and received less transfusion of blood components. TEG analysis showed that patients who received EACA injection had a better coagulation profile and the platelet function was also better after CPB. However, no additive effect can be attained from combination of autologous PRP transfusion and EACA injection. CONCLUSIONS With Pre-CPB EACA as protection, reduction of both blood loss and blood transfusion could be realized in open-heart surgery.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D013916 Thrombelastography Use of a thrombelastograph, which provides a continuous graphic record of the physical shape of a clot during fibrin formation and subsequent lysis. Thromboelastography,Thromboelastometry
D015119 Aminocaproic Acid An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. 6-Aminocaproic Acid,6-Aminohexanoic Acid,epsilon-Aminocaproic Acid,Amicar,CY-116,Capralense,Capramol,Caproamin,Caprocid,Caprolest,Epsamon,Epsikapron,Hemocaprol,Hexalense,6 Aminocaproic Acid,6 Aminohexanoic Acid,CY 116,CY116,epsilon Aminocaproic Acid
D017713 Platelet Transfusion The transfer of blood platelets from a donor to a recipient or reinfusion to the donor. Blood Platelet Transfusion,Blood Platelet Transfusions,Platelet Transfusion, Blood,Platelet Transfusions,Platelet Transfusions, Blood,Transfusion, Blood Platelet,Transfusion, Platelet,Transfusions, Blood Platelet,Transfusions, Platelet

Related Publications

Y C Liu, and T P Tsai
January 1968, Archivos del Instituto de Cardiologia de Mexico,
Y C Liu, and T P Tsai
January 1963, Folia haematologica (Leipzig, Germany : 1928),
Y C Liu, and T P Tsai
June 1969, Veterinariia,
Y C Liu, and T P Tsai
June 1963, Acta medicinae Okayama,
Y C Liu, and T P Tsai
January 1968, Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression,
Y C Liu, and T P Tsai
March 1964, Acta physiologica Scandinavica,
Y C Liu, and T P Tsai
October 2000, The Annals of thoracic surgery,
Y C Liu, and T P Tsai
July 1967, Canadian journal of surgery. Journal canadien de chirurgie,
Copied contents to your clipboard!